New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 2, 2023--
Source: eagletribune.com
Page 5 - Trials Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Trials Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Trials Program Today - Breaking & Trending Today
Bayer's Kerendia® (finerenone) Included in Latest Focused Guideline Clinical Updates from European Society of Cardiology | Business
WHIPPANY, N.J.--(BUSINESS WIRE)--Aug 31, 2023--
Source: valdostadailytimes.com
The Outlast Trials – How To Unlock Program X
Program X isn’t available from the beginning of The Outlast Trials, as you must unlock it. But how? Here, you will find all the information.
Source: wccftech.com
Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
Source: news-medical.net
Monoclonal Antibody Prevents Malaria in Clinical Trial
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite.
Source: technologynetworks.com